New hope for ALS patients: experimental drug aims to slow deadly disease
NCT ID NCT07023835
Summary
This study is testing whether a new oral drug called Usnoflast can slow the progression of ALS (Lou Gehrig's disease). It involves 240 adults with early-stage ALS who will take either the drug or a placebo for 36 weeks, followed by an optional 16-week period where everyone gets the drug. The main goals are to see if the drug helps people maintain physical function and live longer without needing permanent breathing assistance.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zydus 009
Pittsburgh, Pennsylvania, 15212, United States
-
Zydus 100
Québec, Quebec, QC H4A 3T2, Canada
-
Zydus 101
Toronto, Ontario, ON M4N 3M5, Canada
-
Zydus US001
Dallas, Texas, 75206, United States
-
Zydus US002
Houston, Texas, 77030, United States
-
Zydus US003
Winston-Salem, North Carolina, 27157, United States
-
Zydus US004
Richmond, Virginia, 23298, United States
-
Zydus US005
New Britain, Connecticut, 06053, United States
-
Zydus US006
Detroit, Michigan, 48202, United States
-
Zydus US007
Atlanta, Georgia, 30322, United States
-
Zydus US008
Orange, California, 92868, United States
-
Zydus US010
Boston, Massachusetts, 02114, United States
-
Zydus US011
Seattle, Washington, 98122, United States
-
Zydus US012
Tampa, Florida, 80045, United States
-
Zydus US013
San Francisco, California, 94109, United States
-
Zydus US014
Lincoln, Nebraska, 68510, United States
-
Zydus US015
La Jolla, California, 92037, United States
Conditions
Explore the condition pages connected to this study.